PDCD1 and neoplasm: Indeed, in preclinical models with Gal1-KO tumours, this combination (radiation and anti-PD-1 treatment) showed a greater anti-tumour response, with no detectable tumour in 70% of the mice bearing HNC post-radiotherapy initiation [207].